01—Abstract
Summary
Summary of the 8-K filed July 26, 2024. Cited figures are marked; the original filing is the authoritative source.
3M reported second-quarter 2024 results on July 26, 2024, with GAAP net sales of $6.255 billiona (down 0.5% year-over-year) and adjusted net sales of $6.019 billion (up 1.1%, with adjusted organic growth of 1.2%).
GAAP EPS from continuing operations was $2.17b, versus a loss of $(12.94) a year earlier, which was driven by the Combat Arms Earplugs litigation charge in Q2 2023. Adjusted EPS from continuing operations rose 39% to $1.93. Adjusted operating margin expanded 4.4 points to 21.6%, and operating cash flow was $1.0 billion with adjusted free cash flow of $1.2 billion.
The company returned $786 millionc to shareholders through dividends and buybacks in the quarter. The quarter's GAAP results were heavily affected by non-operating items. The most significant was a $2.00 per share gain from the increase in value of 3M's retained Solventum stake, which was partly offset by a $1.09 per share non-cash pension risk transfer charge.
Net litigation costs of $0.44d per share and other special items of $0.23 per share also affected the GAAP figures. Net debt fell sharply to $2.7 billion from $10.2 billion at year-end 2023, following the April 2024 Solventum separation and the associated debt and cash transfers. Cash and equivalents rose to $10.1 billion at June 30, 2024.
Management raised the low end of its full-year 2024 adjusted EPS guidance to $7.00-$7.30 from $6.80-$7.30, while leaving the top end, adjusted organic sales growth (flat to +2%), and adjusted total sales growth (-0.25% to +1.75%) unchanged. New CEO William Brown outlined three priorities: sustained organic growth, improved operational performance, and effective capital deployment. Investors should note that the quarter's reported EPS includes substantial non-recurring items, so adjusted figures and the ongoing PFAS and litigation obligations deserve close attention.
02—Key points
Key Highlights
- Q2 2024 adjusted EPS of $1.93 rose 39% year-over-year, while GAAP EPS from continuing operations was $2.17 versus a $(12.94) loss in Q2 2023 that reflected the earplug litigation charge.
- Adjusted operating income margin reached 21.6%, up 4.4 percentage points year-over-year; GAAP operating margin was 20.3%.
- Adjusted organic sales grew 1.2% year-over-year, while GAAP organic sales declined 0.3%. Adjusted sales excludes manufactured PFAS products that 3M plans to exit by the end of 2025.
- Full-year 2024 adjusted EPS guidance was narrowed to $7.00-$7.30 from $6.80-$7.30, raising the low end; sales guidance was unchanged.
- Net debt declined to $2.7 billion from $10.2 billion at year-end 2023 following the April 2024 Solventum separation; cash and equivalents reached $10.1 billion.
- A $2.00 per share non-cash gain from the rising value of the retained Solventum stake and a $1.09 per share non-cash pension risk transfer charge materially affected GAAP EPS.
- Operating cash flow was $1.0 billion and adjusted free cash flow was $1.2 billion in Q2; 3M returned $786 million to shareholders through dividends and share repurchases.
03—Questions
Frequently Asked Questions
Why is GAAP EPS so much higher than adjusted EPS this quarter?
GAAP EPS of $2.17 exceeds adjusted EPS of $1.93 because of a $2.00 per share non-cash gain from the increase in value of 3M's retained Solventum stake. That gain was partly offset by a $1.09 per share non-cash pension settlement charge from transferring U.S. pension obligations to an insurer, plus $0.44 of litigation costs and $0.23 of other special items. Investors should view the adjusted figure as the better guide to ongoing operating performance.
Did 3M change its full-year 2024 outlook?
Yes, but only modestly. The adjusted EPS range was narrowed to $7.00-$7.30 from $6.80-$7.30, which raises the low end. Adjusted organic sales growth (flat to +2%) and adjusted total sales growth (-0.25% to +1.75%) were unchanged, and the outlook excludes the effect of future acquisitions or divestitures that have not yet closed.
What drove the large year-over-year swing in GAAP results?
The Q2 2023 GAAP loss of $(12.94) per share was driven by a roughly $10.4 billion charge for net costs of significant litigation, mainly related to Combat Arms Earplugs and PFAS-related matters. Q2 2024 had much smaller litigation costs of about $0.44 per share, so the comparison is distorted by that prior-year charge.
How did the Solventum separation affect 3M's balance sheet and cash position?
The April 2024 separation of Solventum shifted substantial debt and cash. Total debt fell to $13.1 billion from $16.0 billion, and net debt dropped to $2.7 billion from $10.2 billion. Cash and marketable securities rose to $10.4 billion. Cash transferred to Solventum totaled $577 million in the first half, and 3M retains a stake in Solventum whose value changes flow through other income.
What are the main risks flagged in the release?
The release highlights ongoing PFAS liabilities, including claims, lawsuits, and government proceedings, as well as the class-action settlement with U.S. public water suppliers. It also notes continuing Combat Arms Earplugs and other significant litigation costs, which were about $428 million in cash payments in Q2 2024 alone. Other risks include foreign currency effects (translation reduced sales by 1.4% in Q2), the timing of the PFAS exit, and the execution of the ERP implementation.
04—Continue